November 1, 2022
Daiichi Sankyo’s April-September sales grew 14.7% year on year despite the termination of its copromotion pact with AstraZeneca for the acid reducer Nexium (esomeprazole). The two-digit growth was driven by major products Lixiana (edoxaban) and Enhertu (trastuzumab deruxtecan) as well...read more